Clinical Research Directory
Browse clinical research sites, groups, and studies.
NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma
Sponsor: AC Camargo Cancer Center
Summary
This is an observational cohort study evaluating clinical and pathological outcomes in patients with high-risk stage II melanoma. Patients are included after receiving treatment as part of routine clinical practice. Decisions about treatment, including whether to start anti-PD1 therapy before surgery, are made by the treating physician and are not influenced by the study. The study compares outcomes between patients who started anti-PD1 therapy before surgery and those treated according to the usual timing in clinical practice. No treatments are assigned as part of the study.
Official title: NEOSENT - Early Anti-PD-1 Therapy In Patients With High-Risk Stage II Melanoma And/Or Microsatellitosis: An Ambispective Observational Cohort Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
250
Start Date
2025-04-23
Completion Date
2027-05
Last Updated
2026-07-02
Healthy Volunteers
No
Conditions
Interventions
Anti-PD1 Therapy Timing
This is an observational study variable. The timing of anti-PD1 therapy initiation in relation to surgery is determined by the treating physician as part of routine clinical practice. The study does not assign or modify any treatment.
Locations (1)
AC Camargo Cancer Center
São Paulo, São Paulo, Brazil